Using advanced imaging to detect and monitor pancreatic cancer
Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
This study is testing a new way to use advanced MRI images to better spot and track pancreatic cancer in patients, helping doctors catch it earlier and manage treatment more effectively.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT06144762 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a model that captures tumor heterogeneity in pancreatic cancer using a multiscale radiomics approach. By obtaining both in vivo and ex vivo MRI images, the study seeks to create a virtual histology representation of tumors, which can be applied to routine clinical MRI for early detection and treatment monitoring. The goal is to provide a comprehensive, non-invasive characterization of pancreatic cancer, addressing the challenges of early diagnosis and effective treatment. This innovative approach could significantly enhance patient management and outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with pathologically proven pancreatic cancer who are eligible for surgery or neoadjuvant chemotherapy.
Not a fit: Patients with metastatic pancreatic cancer or those who will not undergo surgery are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better monitoring of pancreatic cancer, ultimately improving patient survival rates.
How similar studies have performed: While the approach of using radiomics for cancer detection is gaining traction, this specific application in pancreatic cancer is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged \>18 2. * Pathologically proven pancreatic cancer which can beneficiate of upfront surgery or delayed surgery followed by neoadjuvant chemotherapy. * Negative pregnancy test for women of childbearing potential * Patients affiliated to a social protection system * Written informed consent signed before project onset. Exclusion Criteria: * presence of metastases, * Patient who will not have surgery * Pregnant or breastfeeding women * Mental or psychological state, physical or legal incapacity preventing participation in the project.
Where this trial is running
Montpellier
- NOUGARET Stephanie — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: MOUSSION Aurore
- Email: aurore.moussion@icm.unicancer.fr
- Phone: 0467613102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.